107 related articles for article (PubMed ID: 38626341)
1. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma.
Kreuger IZM; Slieker RC; van Groningen T; van Doorn R
J Invest Dermatol; 2023 Jan; 143(1):18-25.e1. PubMed ID: 36123181
[TBL] [Abstract][Full Text] [Related]
3. De Novo Purine Metabolism is a Metabolic Vulnerability of Cancers with Low p16 Expression.
Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Yang B; Chatoff A; Crispim CV; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Lyssiotis CA; Chandran UR; Snyder NW; Aird KM
Cancer Res Commun; 2024 May; 4(5):1174-1188. PubMed ID: 38626341
[TBL] [Abstract][Full Text] [Related]
4. De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression.
Tangudu NK; Buj R; Wang H; Wang J; Cole AR; Uboveja A; Fang R; Amalric A; Sajjakulnukit P; Lyons MA; Cooper K; Hempel N; Snyder NW; Lyssiotis CA; Chandran UR; Aird KM
bioRxiv; 2023 Sep; ():. PubMed ID: 37503050
[TBL] [Abstract][Full Text] [Related]
5. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
7. Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming.
Buj R; Chen CW; Dahl ES; Leon KE; Kuskovsky R; Maglakelidze N; Navaratnarajah M; Zhang G; Doan MT; Jiang H; Zaleski M; Kutzler L; Lacko H; Lu Y; Mills GB; Gowda R; Robertson GP; Warrick JI; Herlyn M; Imamura Y; Kimball SR; DeGraff DJ; Snyder NW; Aird KM
Cell Rep; 2019 Aug; 28(8):1971-1980.e8. PubMed ID: 31433975
[TBL] [Abstract][Full Text] [Related]
8. Frequent genetic defects in the p16/INK4A tumor suppressor in canine cell models of breast cancer and melanoma.
Lutful Kabir FM; DeInnocentes P; Bird AC; Bird RC
In Vitro Cell Dev Biol Anim; 2021 May; 57(5):519-530. PubMed ID: 34014456
[TBL] [Abstract][Full Text] [Related]
9. Insights into Melanoma Clinical Practice: A Perspective for Future Research.
Lam GT; Martini C; Brooks T; Prabhakaran S; Hopkins AM; Ung BS; Tang J; Caruso MC; Brooks RD; Johnson IRD; Sorvina A; Hickey SM; Karageorgos L; Klebe S; O'Leary JJ; Brooks DA; Logan JM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760601
[TBL] [Abstract][Full Text] [Related]
10. Screening in serum-derived medium reveals differential response to compounds targeting metabolism.
Abbott KL; Ali A; Casalena D; Do BT; Ferreira R; Cheah JH; Soule CK; Deik A; Kunchok T; Schmidt DR; Renner S; Honeder SE; Wu M; Chan SH; Tseyang T; Stoltzfus AT; Michel SLJ; Greaves D; Hsu PP; Ng CW; Zhang CJ; Farsidjani A; Kent JR; Madariaga MLL; Gramatikov IMT; Matheson NJ; Lewis CA; Clish CB; Rees MG; Roth JA; Griner LM; Muir A; Auld DS; Vander Heiden MG
Cell Chem Biol; 2023 Sep; 30(9):1156-1168.e7. PubMed ID: 37689063
[TBL] [Abstract][Full Text] [Related]
11. Emerging roles of nucleotide metabolism in cancer.
Shi DD; Savani MR; Abdullah KG; McBrayer SK
Trends Cancer; 2023 Aug; 9(8):624-635. PubMed ID: 37173188
[TBL] [Abstract][Full Text] [Related]
12. Regulation of nucleotide metabolism in cancers and immune disorders.
Ali ES; Ben-Sahra I
Trends Cell Biol; 2023 Nov; 33(11):950-966. PubMed ID: 36967301
[TBL] [Abstract][Full Text] [Related]
13. Senescence and Immunotherapy: Redundant Immunomodulatory Pathways Promote Resistance.
Oesterreich S; Aird KM
Cancer Immunol Res; 2023 Apr; 11(4):401-404. PubMed ID: 36826438
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80.
Shahbandi A; Chiu FY; Ungerleider NA; Kvadas R; Mheidly Z; Sun MJS; Tian D; Waizman DA; Anderson AY; Machado HL; Pursell ZF; Rao SG; Jackson JG
Nat Cancer; 2022 Dec; 3(12):1513-1533. PubMed ID: 36482233
[TBL] [Abstract][Full Text] [Related]
15. Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity.
Chen HA; Ho YJ; Mezzadra R; Adrover JM; Smolkin R; Zhu C; Woess K; Bernstein N; Schmitt G; Fong L; Luan W; Wuest A; Tian S; Li X; Broderick C; Hendrickson RC; Egeblad M; Chen Z; Alonso-Curbelo D; Lowe SW
Cancer Discov; 2023 Feb; 13(2):432-453. PubMed ID: 36302222
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
